Lucid Diagnostics Inc (LUCD): Bathi resik saben saham (EPS TTM)

Physician confidence in esophageal cancer diagnostic methods strengthens the position of Lucid Diagnostics Inc. (LUCD). This 12-month net income per share chart demonstrates the current resilience of the business, where the metric stands at -0.47. The innovative EsoGuard test replaces endoscopy, simplifying screening. The company's strong pricing power is supported by the critical importance of early pathology detection via unique DNA analysis.

LUCD Bathi resik saben saham sajrone patang kuartal pungkasan Lucid Diagnostics Inc. (04.07.2022 - 12.11.2026)

Ringkesan rincian data analitis Lucid Diagnostics, Inc. (LUCD)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Lucid Diagnostics Inc.|LUCD - Target median analis

- data kapitalisasi bursa:

Kapitalisasi pasar Lucid Diagnostics Inc.|LUCD - Rega Tumbas Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Lucid Diagnostics|LUCD - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku luciddx.com|LUCD - Aset Agregat Perusahaan

- indikator beban kredit lan likuiditas emiten:

Rasio Total Utang marang Ekuitas Lucid Diagnostics Inc.|LUCD - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Lucid Diagnostics Inc|LUCD - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Lucid Diagnostics Inc.|LUCD - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Lucid Diagnostics|Indikator likuiditas cepet luciddx.com

- data bathi lan kelipatan valuasi:

LUCD - Bathi pungkasan|Proyeksi bathi mangsa ngarep Lucid Diagnostics Inc.|LUCD - Pangali rega marang bathi|Pangali Forward P/E Lucid Diagnostics|LUCD - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Lucid Diagnostics Inc.|LUCD - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Lucid Diagnostics|LUCD - Bathi resik saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan luciddx.com|LUCD - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Lucid Diagnostics Inc.

Analisis wiwitan perusahaan:Lucid Diagnostics Inc. (LUCD)

The commercialization efficiency of EsoGuard tests for diagnosing precancerous esophageal conditions is directly reflected in the earnings per share dynamics of Lucid Diagnostics Inc. (LUCD). This calculation combines annual net income with the total number of issued shares, allowing for an assessment of the business's real profitability amid tight monetary policy. Analyzing the TTM annual earnings per share helps investors recognize the risk of overpaying for the asset in a timely manner.

Pesaing Lucid Diagnostics Inc.